 |
|
|
| |
Association of Post-treatment Virologic Relapse and Biochemical Flares With HBV Serum Biomarkers in Long-term Virologically Suppressed HBeAg negative Patients Stopping NA Treatment: Exploratory Analyses From the Control Arm of the REEF-2 Study
|
| |
| |
EASL 2023 June 21-24 Vienna
Florian van Bömmel,1,* Thierry Verbinnen,2 Kosh Agarwal,3 Thomas Vanwolleghem,4 Pietro Lampertico,5,6 Maria Buti,7 Ewa Janczewska,8 Marc Bourliere,9 John Jezorwski,10 Kathleen Donohue,11 Gloria Kim,12 Thomas N. Kakuda,13 Sandra De Meyer,2 Adam Bakala,2 Oliver Lenz,2 Michael Biermer
1Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany; 2Janssen Pharmaceutica NV, Beerse, Belgium; 3Institute of Liver Studies, King's College Hospital, Denmark Hill, London, UK; 4University of Antwerp, Faculty of Medicine & Health Sciences, Laboratory of Experimental Medicine & Pediatrics, Viral Hepatitis Research Group, Antwerp, Belgium; 5Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; 6CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; 7Hospital General Universitari Vall Hebron and CIBER EHD del Instituto Carlos III, Barcelona, Spain; 8Medical University of Silesia in Katowice, Faculty of Public Health in Bytom, Bytom, Poland; 9Hôpital Saint-Joseph, Department of Hepatology and Gastroenterology, Marseille, France; 10Janssen Research & Development, LLC, Titusville, NJ, USA; 11Cytel Inc., Waltham, MA, USA; 12IQVIA, Durham, NC, USA; 13Janssen Research & Development, LLC, Brisbane, CA, USA.
|
| |
|
|
|
|
|
